Vestal Point Capital, LP - 30 Jun 2025 SCHEDULE 13G/A Report for Dianthus Therapeutics, Inc. /DE/ Common Stock, par value $0.001 per share (DNTH)

Filing Manager
Vestal Point Capital, LP
Reporting Manager
Vestal Point Capital, LP
Security
Dianthus Therapeutics, Inc. /DE/ Common Stock, par value $0.001 per share
Symbol
DNTH
Shares outstanding
32,160,804 shares
Disclosed Ownership
3,200,000 shares
Ownership
10%
Form type
SCHEDULE 13G/A
Filing time
14 Aug 2025, 15:47:37 UTC
Date of event
30 Jun 2025
Previous filing
15 May 2025
Next filing
14 Nov 2025
SEC
View on sec.gov

Sponsored

Quoteable Key Fact

"Vestal Point Capital, LP disclosed 10% ownership in Dianthus Therapeutics, Inc. /DE/ Common Stock, par value $0.001 per share (DNTH) on 30 Jun 2025."

Quick Takeaways

  • Vestal Point Capital, LP filed SCHEDULE 13G/A for Dianthus Therapeutics, Inc. /DE/ Common Stock, par value $0.001 per share (DNTH).
  • Disclosed ownership: 10%.
  • Date of event: 30 Jun 2025.

What Changed

  • Previous schedule filing date: 15 May 2025.
  • Current filing was accepted on 14 Aug 2025, 15:47.

Why This Matters

  • This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
  • You can verify ownership claims directly against the original SEC filing.

Official SEC Source

Backed by Schedule 13D/13G

Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.

See Original Filing

Reporting Managers (2)

Name Ownership Shares Owned sole voting power shared voting power Signature Title CIK
Vestal Point Capital, LP 10% 3,200,000 0 3,200,000 /s/ Ryan Wilder By: Vestal Point Capital, LLC, General Partner, By: Ryan Wilder, Chief Investment Officer and Managing Partner
Ryan Wilder 10% 3,200,000 0 3,200,000 /s/ Ryan Wilder Ryan Wilder, Individually

Sponsored